Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LODOCO STINT Pilot Study
NCT06874192Phase 1Completed
- Sponsor
- Virginia Commonwealth University
- Start
- Mar 2025
- Primary completion
- May 2026
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of colchicine in statin intolerance (SAMS) (2 arms), sponsored by Virginia Commonwealth University. Primary endpoints: Incidence of adverse events at 4 weeks and Change in high-sensitivity C-reactive protein at 4 weeks. Started Mar 2025; status: completed.
02
Drugs
colchicine
03
Conditions
statin intolerance (SAMS)
Beyond the preview
Go deeper on NCT06874192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06874192.